Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination

Future Oncology

Volumn 3, Issue 3, 2007, Pages 319-327

  Franco, Eduardo L ^a   Ferenczy, Alex ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cervarix ; Cervical cancer; Gardasil ; Human papillomavirus testing; Pap cytology; Prophylaxis screening; Vaccines

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; DNA DETERMINATION; FALSE NEGATIVE RESULT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOSURVEILLANCE; NONHUMAN; PAPANICOLAOU TEST; PRECANCER; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VIRUS INFECTION; WOMEN'S HEALTH;

CLINICAL TRIALS; DNA, VIRAL; FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS;

EID: 34347380761     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.3.319     Document Type: Review

References (33)

1. Franco EL, Duarte-Franco E, Ferenczy A: Cervical cancer: epidemiology, prevention, and role of human papillomavirus infection. Can. Med. Assoc. J. 164, 1017-1025 (2001).
2. Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030-3044 (2006).
3. IARC Working Group: human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 64, International Agency for Research on Cancer, Lyon, France (1995).
4. Munoz N, Bosch FX, de Sanjose S et al.: Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348(6), 518-527 (2003).
5. Trottier H, Franco EL: The epidemiology of genital human papillomavirus infection. Vaccine 24(Suppl. 1), S1-S15 (2006).
6. Benard VB, Eheman CR, Lawson HW et al.: Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001. Obstet. Gynecol. 103. 564-571 (2004).
7. Nanda K, McCrory DC, Myers ER et al.: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 132, 810-819 (2000).
8. Davey E, Barratt A, Irwing L et al.: Effect of study design and quality on unsatisfactory rates, cytology classifications and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 367, 122-132 (2006).
9. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J: Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade Intraepithelial neoplasia. J. Natl Cancer Inst. 96, 280-293 (2004).
10. Franco EL: Primary screening of cervical cancer with human papillomavirus tests. J. Natl Cancer Inst. Monogr. 31, 89-96 (2003).
11. IARC Working Group: Cervix cancer screening. IARC Handbooks of Cancer Prevention. International Agency for Research on Cancer, World Health Organization, IARC Press (2005).
12. Cuzick J, Clavel C, Petry KU et al.: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119, 1095-1105 (2006).
13. Arbyn M, Sasieni P, Meijer Q, Clavel C. Kollopoulos G, Dillner J: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl. 3), S78-S89(2006).
14. Wright TC Jr, Schiffman M, Solomon D et al.: Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet. Gynecol. 103(2), 304-309 (2004).
15. Bulknians NW, Rozendaal L, Snijders PJ et al.: POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int. J. Cancer 110(1), 94-101 (2004).
16. Kitchener HC, Almonte M, Wheeler P et al.: ARTISTIC Trial Study Group. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br. J. Cancer 95(1), 56-61 (2006).
17. Elfgren K, Rylander E, Radberg T et al.: Swedescreen Study Group. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am. J. Obstet. Gynecol. 193(3 Pt 1), 650-657 (2005).
18. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M: Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br. J. Cancer. 93(8), 862-867 (2005).
19. Ronco G, Segnan N, Giorgi-Rossi P et al.: New Tecimologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J. Natl Cancer Inst. 98(11), 765-774 (2006).
20. Mayrand MH, Duarte-Franco E, Coutlee F et al.: Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int. J. Cancer 119, 615-623 (2006).
21. Franco EL, Harper DM: Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 23, 2388-2394 (2005).
22. Koutsky LA, Ault KA, Wheeler CM et al.: A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 (2002).
23. Harper DM, Franco EL, Wheeler C et al.: Giaxo Smith Kline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 364, 1757-1765 (2005).
24. Villa LL, Costa RL, Petta CA et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. 6, 271-278 (2005).
25. Mao C, Koutsky LA, Ault KA et al.: Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 107, 18-27 (2006).
26. Harper DM, Franco EL, Wheeler CM et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillornavinis types 16 and 18. Results from a randomized controlled trial in young women. Lancet 367, 1247-1255 (2006).
27. Vilia LL, Costa RL, Petta CA et al.: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer. 95(11), 1459-1466 (2006).
28. Kuiasingam SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290, 781-789 (2003).
29. Goldie SJ, Kohli M, Grinia D et al.: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J. Natl Cancer Inst. 96, 604-615 (2004).
30. Taira AV, Neukermans CP, Sanders GD: Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis. 10, 1915-1923 (2004).
31. Munoz N, Bosch FX, Castellsague X et al.: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111. 278-285 (2004).
32. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G. Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol. Biomarkers Prev. 14, 1157-1164 (2005).
33. Franco EL, Cuzick J, Hildesheim A, de Sanjose S: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24(Suppl. 3), S171-SI77 (2006).